GlaxoSmithKline Settles Most Zantac Lawsuits for $2.2B
The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain
GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...
葛兰素史克(GSK.US)同意支付22亿美元以解决约8万起胃灼热药物Zantac ...
智通财经获悉，葛兰素史克(GSK.US)周三宣布，该公司已同意支付高达22亿美元，以解决美国州法院提起的大多数诉讼，这些诉讼指控一种已停产的胃灼热药物Zantac会导致癌症。该公司说，与10家原告律师事务所达成的协议解决了约8万起案件，占美国全国州法 ...
GSK Rises After Settling Zantac Cases for Up to $2.2 Billion
GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court ...
GSK settles vast majority of Zantac claims for $2.2 billion
The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn ...
BioSpace5 天
GSK Settles Zantac Lawsuits for $2.2B, Analysts Now Shift Focus to Vaccines
The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the ...
WJET Erie on MSN5 天
Drugmaker to settle nearly 80,000 Zantac lawsuits for up to $2.2 billion
UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...
阿思達克財經網5 天
葛兰素史克(GSK.US)同意支付22亿美元以解决约8万起胃灼热药物Zantac ...
Zantac于1983年首次获得美国监管机构的批准，并于1988年成为世界上最畅销的药物，也是首批年销售额超过10亿美元的药物之一。这种药物在不同时期由 ...
GSK shares leap after drug firm settles US Zantac cancer claim lawsuit
GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies ...
GlaxoSmithKline股票前景因美国Arexvy销售不及预期而被修正 - 杰富瑞证券
周四，全球投资银行杰富瑞证券调整了GlaxoSmithKline (GSK:LN) (NYSE: GSK)的股票目标价，将其从之前的21.00英镑下调至20.00英镑。尽管如此，该公司仍维持对这家制药公司股票的"买入"评级。 此次修正是因为分析师预计GlaxoSmithKline第三季度的销售和利润可能低于市场预期，主要原因是美国Arexvy的表现不如预期。然而，分析师指出，该公司预计将重申其20 ...